| Form | Liquid |
|---|---|
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Purification | Purified by antigen affinity column. |
| Endotoxin Level | Please contact with the lab for this information. |
| Applications | ELISA, IHC, WB |
| Species Reactivity | Human |
| Target | ADAL, ADAL1, Adenosine deaminase-like protein, EC:3.5.4.-, HsMAPDA, MAPDA, N6,N6-dimethyl-AMP deaminase, N6-Methyl-AMP deaminase, N6-isopentenyl-AMP deaminase, N6-mAMP deaminase, N6-methyl-AMP aminohy |
| Immunogen | E. coli - derived recombinant Human MAPDA (Met1-Ile355). |
| Storage Buffer | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
| Product Usage Information | ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000 |
| Accession Number | Q6DHV7 |
| Background | N6-Methyl-AMP deaminase (MAPDA) is a ~40 kDa protein. Deaminase involved in the detoxification of modified adenosines containing N(6)-methylated adenine (m6A) post-transcriptional modification. Modified nucleosides are derived from the degradation of RNAs (mRNAs, rRNAs and tRNAs) and possess intrinsic cytotoxicity and must be cleared to prevent metabolic dysfunction. Acts downstream of ADK and catalyzes the hydrolysis of the free cytosolic methylated adenosine nucleotides N(6)-methyl-AMP (m6AMP), N(6),N(6)-dimethyl-AMP (m6,6AMP) and N(6)-isopentenyl-AMP (i6AMP) to produce inositol monophosphate (IMP). Catalyzes the removal of different alkyl groups not only from N6-substituted purine or 2-aminopurine nucleoside monophosphates but also from O6-substituted compounds in vitro. 1. Ogawa, A. et al. (2025) Cell 188, 6151-6169.e24. PMID: 40840445 2. Murakami, E. et al. (2011) Journal of medicinal chemistry 54, 5902-14. PMID: 21755941 3. Chen, M. et al. (2018) The Plant cell 30, 1511-1522. PMID: 29884623 |
| Note | For research use only |